US 12,264,163 B2
Compounds and methods for treating fibrotic pathologies
Daniel J. Tschumperlin, Rochester, MN (US); and Andrew J. Haak, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Appl. No. 17/625,244
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
PCT Filed Jul. 29, 2020, PCT No. PCT/US2020/044054
§ 371(c)(1), (2) Date Jan. 6, 2022,
PCT Pub. No. WO2021/021922, PCT Pub. Date Feb. 4, 2021.
Claims priority of provisional application 62/880,494, filed on Jul. 30, 2019.
Claims priority of provisional application 62/880,594, filed on Jul. 30, 2019.
Prior Publication US 2022/0275002 A1, Sep. 1, 2022
Int. Cl. C07D 401/12 (2006.01); A61K 31/454 (2006.01); A61P 19/04 (2006.01); C07D 217/02 (2006.01); C07D 401/04 (2006.01); C07D 405/04 (2006.01); C07D 407/04 (2006.01); C07D 471/06 (2006.01); C07D 491/052 (2006.01); C07D 491/06 (2006.01); C07D 491/16 (2006.01)
CPC C07D 491/16 (2013.01) [A61P 19/04 (2018.01); C07D 217/02 (2013.01); C07D 401/04 (2013.01); C07D 405/04 (2013.01); C07D 407/04 (2013.01); C07D 471/06 (2013.01); C07D 491/052 (2013.01); C07D 491/06 (2013.01)] 13 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from 5-6-membered heteroaryl ring comprising 1 to 5 heteroatoms selected from N, O, and S;
wherein said heteroaryl ring is optionally substituted with 1, 2, or 3 substituents independently selected from R2;
each R2 is independently selected from halo, OH, C1-3 alkoxy, SH, NH2, C1-3 alkylamino, di(C1-3 alkyl)amino, C1-3 alkyl, and C1-3 haloalkyl, wherein said C1-3 alkyl is optionally substituted with OH, C1-3 alkoxy, SH, NH2, C1-3 alkylamino, and di(C1-3 alkyl)amino; and
R3 is selected from H and halo.